

04/12/01

JCS660 U.S. PTO

Please type a sign (+) inside this box

+ PTO/SB/05 (08-00)

Approved for use through 10/31/2002. OMB 0651-0052  
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.PTO  
11/13/98  
09/09/01  
C-98-01  
S n V98

04/12/01

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.13(b))

Attorney Docket No. PF548  
First Inventor ROSEN et al  
Title **ALBUMIN FUSION PROTEINS**  
Express Mail Label No.

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 1-546]  
(preferred arrangement set forth below)
  - Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the invention
  - Brief Summary of the invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) (Figs 1-14, 15A-15D)  
[Total Sheets 18]
5. ☒ Oath or Declaration (unexecuted) [Total Pages 2]
  - a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)
  - i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.163(d)(2) and 1.33(b).
6. ☒ Application Data Sheet. See 37 CFR 1.76.

**ADDRESS TO:**

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. ☒ Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a. ☒ Computer Readable Form (CRF)
  - b. ☒ Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☒ paper
  - c. ☐ Statements verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

9. ☐ Assignment Papers (cover sheet and document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement/ Form PTO/SB/08  
☐ Copies of Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)  
(should be specifically stamped)
15. ☐ Certified copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior application No. \_\_\_\_/  
Prior application information Examiner Group/Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation may only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**18. CORRESPONDENCE ADDRESS**

☒ Customer Number or Bar Code Label **22195** or ☐ Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

NAME (Print/Type)

Michele M. Wales

Registration No. (Attorney/Agent)

43,975

SIGNATURE

*Michele M. Wales*

Date April 12, 2001

This statement is true and correct to the best of my knowledge and belief. I am not aware of any other person who is or has been involved in the preparation or filing of this application. Any comments on the amount of time you are required to complete this statement should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**FEE TRANSMITTAL  
for FY 2001***Patent fees are subject to annual revision.***Complete if Known**

Application Number	To be assigned
Filing Date	April 12, 2001
First Named Inventor	ROSEN et al.
Examiner Name	To be assigned
Group Art Unit	To be assigned
Attorney Docket Number	PF548

Total amount of payment **\$4,390.00****METHOD OF PAYMENT**

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **08-3425**Deposit Account Name **Human Genome Sciences, Inc.**

- ☒ Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17

- ☐ Applicant claims small entity status See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit Card ☐ Money Order ☐ Other

**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Fee Code (S)	Small Entity Fee Code (S)	Fee Description	Fee Paid
101 710 201 355		Utility filing fee	710.00
106 320 206 160		Design filing fee	
197 490 207 245		Plant filing fee	
108 710 208 355		Reissue filing fee	
114 150 214 75		Provisional filing fee	

**SUBTOTAL (1) \$710.00****2. EXTRA CLAIM FEES**

Total Claims	Independent Claims	Multiple Dependent	Extra Claims	Fee from below	Fee Paid
205	4		185	\$18.00	\$3330
			1	\$80.00	\$80
				\$270.00	\$270

Large Entity Fee Code (S)	Small Entity Fee Code (S)	Fee Description	Fee Paid
103 18 203 9		Claims in excess of 20	
102 80 202 40		Independent claims in excess of 3	
104 270 204 135		Multiple dependent claims, if not paid	
108 80 208 40		** Reissue independent claims over original patent	
110 18 210 9		** Reissue claims in excess of 20 and over original patent	

**SUBTOTAL (2) \$3,680.00**

\*\* or number previously paid, if greater. For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity Fee Code (S)	Small Entity Fee Code (S)	Fee Description	Fee Paid
105 130 205 65		Surcharge - late filing fee or oath	
127 30 227 25		Surcharge - late provisional filing fee or cover sheet	
139 130 139 130		Non-English specification	
147 2,520 147 2,520		For filing a request for <i>ex parte</i> reexamination	
112 920* 112 920*		Requesting publication of SIR prior to Examiner action	
113 1,840* 113 1,840*		Requesting publication of SIR after Examiner action	
115 110 215 55		Extension for reply within first month	
116 390 216 195		Extension for reply within second month	
117 890 217 445		Extension for reply within third month	
118 1,390 218 695		Extension for reply within fourth month	
128 1,890 228 945		Extension for reply within fifth month	
119 310 219 155		Notice of Appeal	
120 310 220 155		Filing a brief in support of an appeal	
121 270 221 135		Request for oral hearing	
138 1,510 138 1,510		Petition to institute a public use proceeding	
140 110 240 55		Petition to revive - unavoidable	
141 1,240 241 620		Petition to revive - unintentional	
142 1,240 242 620		Utility issue fee (or reissue)	
143 440 243 220		Design issue fee	
144 600 244 300		Plant issue fee	
122 130 122 130		Petitions to the Commissioner	
123 30 123 30		Petitions related to provisional applications	
126 180 126 180		Submission of Information Disclosure Statement	
581 40 481 40		Recording each patent assignment per property (times number of properties)	
146 710 246 355		Filing a submission after final rejection (37 CFR 1.129(a))	
149 710 249 355		For each additional invention to be examined (37 CFR 1.129(b))	
179 710 279 355		Request for Continued Examination (RCE)	
169 900 169 900		Request for expedited examination of a design application	
		Other fee (specify):	
		Other fee (specify):	
		* Reduced by Basic Filing Fee Paid	
		<b>SUBTOTAL (3) \$0.00</b>	

**Submitted By**Name (Print/Type) **Michele M. Wales**Registration No.: **43,975**Telephone **301-610-5772**Signature: *Michele M. Wales*Date: **4/12/01**

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

VIA HAND DELIVERY APRIL 12, 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: ROSEN et al.

Application Serial No.: to be assigned

Art Unit: to be assigned

Filed: April 12, 2001

Examiner: to be assigned

For: ALBUMIN FUSION PROTEINS

Attorney Docket No.: PF548

**STATEMENT UNDER 37 C.F.R. 1.821(d)**


Commissioner For Patents  
Washington, D.C. 20231

Sir:

Applicants hereby certify that the enclosed paper copy of the sequence listing and the computer-readable form of such sequence listing are identical.

Respectfully submitted,

Dated: April 12, 2001

  
Michele M. Wales (Reg. No. 43,975)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, Maryland 20850  
Telephone: 301-610-5772

Enclosure  
MMW/ts